Apollon Wealth Management LLC Sells 702 Shares of DexCom, Inc. (NASDAQ:DXCM)

Apollon Wealth Management LLC lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,703 shares of the medical device company’s stock after selling 702 shares during the period. Apollon Wealth Management LLC’s holdings in DexCom were worth $1,377,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Versant Capital Management Inc bought a new stake in shares of DexCom in the 4th quarter valued at about $25,000. Riverview Trust Co increased its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. Heck Capital Advisors LLC bought a new position in DexCom in the fourth quarter worth approximately $38,000. RPg Family Wealth Advisory LLC bought a new position in DexCom in the third quarter worth approximately $57,000. Finally, Covestor Ltd lifted its holdings in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after buying an additional 335 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Up 0.2 %

Shares of NASDAQ:DXCM opened at $88.27 on Tuesday. The business has a 50-day moving average price of $81.76 and a 200-day moving average price of $75.11. The stock has a market cap of $34.48 billion, a price-to-earnings ratio of 52.86, a PEG ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Raymond James reduced their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group raised their price target on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 9th. Wells Fargo & Company boosted their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Citigroup raised their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $98.41.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.